Here's Why Agios Pharmaceuticals Crashed 23% Today
Key Points
Agios Pharmaceuticals shares dropped 23% following Novo Nordisk's trial results.
Novo's etavopivat outperformed Agios' mitapavit in key sickle cell endpoints, Novo plans to file for FDA approval in late 2026, threatening Agios' market potential.
- 10 stocks we like better than Agios Pharmaceuticals ›
Shares in Agios Pharmaceuticals (NASDAQ: AGIO) slumped by 23% as of 11 a.m. today. As is often the case with small-cap healthcare stocks, the move isn't so much dictated by what the company is doing as by what a much larger company, Novo Nordisk (NYSE: NVO), reported today.
What happened wth Novo Nordisk today
In case you are wondering, Novo Nordisk stock barely moved today. It's a performance that reflects the relative importance of healthcare companies' sickle cell treatments to their respective bottom lines. Today's news was that Novo's oral, once-daily, pyruvate kinase-R (PKR) activator, etavopivat, is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, according to Novo's release.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
This stands in contrast to the Phase 3 data from Agios (released in November) with its oral pyruvate kinase activator, mitapavit, in sickle cell disease. Improving hemoglobin levels in patients with sickle cell disease helps reduce anemia and, ultimately, should reduce crisis events, including intense pain episodes.
In short, Novo's etavopivat improved hemoglobin response and demonstrated a statistically significant reduction in vaso-occlusive crisis (VOC), with Novo noting that the "time to first" VOC occurred at 38.4 weeks in the treatment group compared to 20.9 weeks in the placebo group.
Agios trial result
In contrast, Agios' mitapavit, although also improving hemoglobin response, didn't demonstrate a statistically significant improvement in its primary endpoint of reducing "annualized rate of sickle cell pain crises (SCPCs) compared to placebo."
Image source: Getty Images.
As such, the news from Novo, and its intent to file for FDA approval in the second half of 2026 is a clear threat to the earnings potential of Agios' mitapavit, even as it works with the FDA to "achieve alignment on the confirmatory clinical trial required for submission."
Clearly, Agios ' path to approval is longer and probably more uncertain.
Should you buy stock in Agios Pharmaceuticals right now?
Before you buy stock in Agios Pharmaceuticals, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Agios Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $524,786!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,236,406!*
Now, it’s worth noting Stock Advisor’s total average return is 994% — a market-crushing outperformance compared to 199% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of April 20, 2026.
Lee Samaha has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
Recommended Articles
